The Community Oncology Alliance (COA) created its Payer Exchange Summit to get payers who are thinking about getting involved in oncology payment reform or want to know what to do exposed to successful pilots, explained Ted Okon, MBA, executive director of COA.
The Community Oncology Alliance (COA) created its Payer Exchange Summit to get payers who are thinking about getting involved in oncology payment reform or want to know what to do exposed to successful pilots, explained Ted Okon, MBA, executive director of COA.
Transcript (slightly modified for readability)
What is the objective of the Community Oncology Alliance's Payer Exchange Summit?
So at COA we had this dream over a year ago of getting providers and payers together at a summit. In fact, we called it the Payer Exchange Summit on Oncology Payment Reform. We wanted to get provider and payer teams that were actually working on oncology payment reform to talk about "what are we doing? What's working? What's not working?"
So now that we've done the first summit a year ago, we did the second summit when we devoted half a day at our conference in April, and now that we've just finished the third summit, we're really seeing a great opportunity here to get more payers involved in the dialogue. Not just the really progressive payers that are actually doing things in oncology payment reform, like Aetna, like UnitedHealthcare, but literally to get payers that are thinking about doing something or want to know what they should be doing to literally have them exposed to pilots that are working now with actual payers and providers.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Semaglutide Eligibility Expands to Over Half of US Adults
November 21st 2024Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.
Read More
Frameworks for Advancing Health Equity: Health Equity by Design
July 23rd 2024Melissa Clarke, MD, CMQ, the chief health equity officer at Elevance Health, explains "Health Equity by Design" and how Elevance Health is committed to ensuring a personalized and intentional approach for all its members.
Listen